These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24349627)

  • 1. Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
    Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr W; Menon M; Sarkar F
    Am J Transl Res; 2013; 6(1):102-103. PubMed ID: 24349627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
    Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
    Am J Transl Res; 2012; 4(1):14-23. PubMed ID: 22347519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
    Kashat M; Azzouz L; Sarkar SH; Kong D; Li Y; Sarkar FH
    Am J Transl Res; 2012; 4(4):432-42. PubMed ID: 23145211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
    Kong D; Sethi S; Li Y; Chen W; Sakr WA; Heath E; Sarkar FH
    Prostate; 2015 Feb; 75(2):161-74. PubMed ID: 25307492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.
    Li Y; Sarkar FH
    Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):11-7. PubMed ID: 26501150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.
    Kong D; Heath E; Chen W; Cher ML; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
    PLoS One; 2012; 7(3):e33729. PubMed ID: 22442719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.
    Singh-Gupta V; Banerjee S; Yunker CK; Rakowski JT; Joiner MC; Konski AA; Sarkar FH; Hillman GG
    Cancer Lett; 2012 May; 318(1):86-92. PubMed ID: 22155105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigallocatechin-3-gallate Enhances the Efficacy of MicroRNA-34a Mimic and MicroRNA-93 Inhibitor Co-transfection in Prostate Cancer Cell Line.
    Mokhtari H; Yaghmaei B; Sirati-Sabet M; Jafari N; Mardomi A; Abediankenari S; Mahrooz A
    Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):612-623. PubMed ID: 33463130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
    Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development.
    Li WJ; Liu X; Dougherty EM; Tang DG
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.
    Hwang C; Sethi S; Heilbrun LK; Gupta NS; Chitale DA; Sakr WA; Menon M; Peabody JO; Smith DW; Sarkar FH; Heath EI
    Am J Transl Res; 2016; 8(1):166-76. PubMed ID: 27069550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.